GlassScriptPhysician profile
Walid L Shaib
NPI 1831372481
$217,067.45
in general payments reported to CMS, 2019-2025
64 companies · $130K in 2025
The $130K reported for 2025 was more than what 99% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,339 · 2020: $8,995 · 2021: $14.96 · 2022: $14K · 2023: $24K · 2024: $33K · 2025: $130K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $79K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $51K · Consulting Fee: $26K · Travel and Lodging: $19K · Food and Beverage: $9,049 · Honoraria: $2,825 · Education: $673.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $78,622.92 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $51,335.00 |
| Consulting Fee | $26,265.00 |
| Travel and Lodging | $18,909.18 |
| Food and Beverage | $9,048.62 |
| Honoraria | $2,825.00 |
| Education | $673.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exelixis INC. | $65,963.35 | 2020-2025 | Cabometyx |
| Jazz Pharmaceuticals INC. | $37,349.19 | 2024-2025 | |
| Seagen INC. | $31,805.77 | 2022-2023 | Tukysa, Adcetris, Padcev |
| Astrazeneca Pharmaceuticals LP | $25,688.30 | 2022-2025 | Imfinzi, Lynparza, Truqap |
| Pfizer INC. | $14,979.88 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $8,217.10 | 2020-2025 | Opdivo |
| Lexicon Pharmaceuticals, INC. | $5,731.71 | 2020 | |
| Incyte Corporation | $5,238.91 | 2025 | Zynyz, Jakafi |
| Mylan Institutional INC. | $3,436.69 | 2019 | |
| Eisai INC. | $2,944.31 | 2019-2025 | |
| Adc Therapeutics America, INC. | $2,400.00 | 2024 | |
| Janssen Scientific Affairs, LLC | $2,310.00 | 2025 | |
| Tersera Therapeutics LLC | $1,546.69 | 2022-2025 | Xermelo, Zoladex |
| Taiho Oncology, INC. | $1,400.00 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $1,035.27 | 2020-2025 |
Show all 62 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Array Biopharma INC | $854.63 | 2024-2025 | Braftovi, Mektovi, Lorbrena |
| Janssen Biotech, INC. | $724.11 | 2022-2025 | Darzalex, Tecvayli, Talvey |
| Cumberland Pharmaceuticals, INC. | $519.75 | 2022-2025 | Sancuso |
| Merck Sharp & Dohme LLC | $446.35 | 2022-2025 | Keytruda, Welireg, Lynparza |
| Celgene Corporation | $411.43 | 2022-2025 | Reblozyl, Pomalyst |
| Sobi, INC | $375.28 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $357.77 | 2022-2025 | |
| Daiichi Sankyo INC. | $338.15 | 2022-2025 | Enhertu, Injectafer, Datroway |
| Abbvie INC. | $282.59 | 2024-2025 | |
| Genentech USA, INC. | $273.95 | 2022-2024 | Rozlytrek, Alecensa, Tecentriq |
| Gilead Sciences, INC. | $202.42 | 2022-2025 | Trodelvy |
| Rigel Pharmaceuticals, INC. | $186.67 | 2023-2024 | Rezlidhia, Tavalisse |
| Boston Scientific Corporation | $165.82 | 2024 | Therasphere Y90 Glass Microspheres 10 Gbq |
| Regeneron Healthcare Solutions, INC. | $160.19 | 2022-2025 | Libtayo |
| Glaxosmithkline, LLC. | $149.27 | 2022-2025 | Ojjaara, Jemperli |
| Karyopharm Therapeutics INC. | $125.10 | 2022-2025 | Xpovio |
| Alexion Pharmaceuticals, INC. | $124.24 | 2023-2025 | Soliris, Ultomiris |
| Advanced Accelerator Applications | $120.06 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $119.78 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $97.98 | 2024 | Fruzaqla |
| Astellas Pharma US INC | $96.77 | 2023-2025 | Padcev |
| Amgen INC. | $91.91 | 2022 | |
| Beone Medicines USA, INC. | $87.99 | 2025 | Brukinsa |
| Lilly USA, LLC | $67.24 | 2022-2023 | Jaypirca, Verzenio, Retevmo |
| Caris Mpi, INC. | $53.21 | 2025 | Mi Cancer Seek |
| Puma Biotechnology, INC. | $46.29 | 2024 | |
| Deciphera Pharmaceuticals INC. | $43.01 | 2024-2025 | Qinlock, Romvimza |
| Genzyme Corporation | $41.69 | 2024 | |
| Mirati Therapeutics, INC. | $39.73 | 2023-2024 | Krazati |
| Springworks Therapeutics, INC. | $39.51 | 2024-2025 | Ogsiveo |
| Agios Pharmaceuticals, INC. | $39.18 | 2025 | Pyrukynd |
| Beigene USA, INC. | $36.79 | 2022-2024 | Brukinsa |
| Syndax Pharmaceuticals, INC. | $34.90 | 2025 | |
| Foundation Medicine, INC. | $27.67 | 2023 | Foundationone Liquid Cdx |
| Aveo Pharmaceuticals, INC. | $26.23 | 2024 | |
| Stemline Therapeutics INC. | $25.80 | 2025 | Orserdu |
| Cti Biopharma Corp. | $21.52 | 2022 | |
| Adaptive Biotechnologies Corporation | $21.43 | 2022 | |
| Pharmaessentia USA Corporation | $18.83 | 2025 | Besremi |
| Emd Serono, INC. | $17.51 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.40 | 2025 | |
| Werfen USA LLC | $17.05 | 2023 | |
| Acrotech Biopharma INC. | $15.26 | 2025 | Beleodaq |
| Kite Pharma, INC. | $15.05 | 2022 | |
| Helsinn Therapeutics (U.S.), INC. | $14.96 | 2021 | |
| Geron Corporation | $14.55 | 2025 | Rytelo |
| G1 Therapeutics, INC. | $13.26 | 2023 | Cosela |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Walid Shaib listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.